IMMUTEP Ltd (IMMP) stock
IMMPNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRRUF
$3.25−0.01 (-0.31%)
Close on Nov 18, 2026Market cap $23.95MP/E –Yield –
Immutep revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2026 it was A$24.17M, up 133.9% from the year before. Over ten years it grew 28.1% a year on average. The highest annual figure on record is A$24.17M in fiscal 2026.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | A$24.17M | +133.9% |
| FY2025 | Jun 30, 2025 | A$10.33M | +31.8% |
| FY2024 | Jun 30, 2024 | A$7.84M | +50.7% |
| FY2023 | Jun 30, 2023 | A$5.20M | -23.1% |
| FY2022 | Jun 30, 2022 | A$6.76M | +70.3% |
| FY2021 | Jun 30, 2021 | A$3.97M | -76.0% |
| FY2020 | Jun 30, 2020 | A$16.50M | +120.3% |
| FY2019 | Jun 30, 2019 | A$7.49M | +1.9% |
| FY2018 | Jun 30, 2018 | A$7.35M | +74.2% |
| FY2017 | Jun 30, 2017 | A$4.22M | +108.1% |
| FY2016 | Jun 30, 2016 | A$2.03M | – |
See a number that looks wrong?